United Kingdom
UK clinical-trial planning follows its own regulatory route.
The UK is outside the EU CTIS process and requires planning around current MHRA requirements.
Plan UK activities alongside EU/EEA activities.
For medicinal-product trials, the Medicines and Healthcare products Regulatory Agency publishes the application guidance. A programme involving EU/EEA and UK sites requires a coordinated plan across separate submission routes, timelines and national requirements.
